Table 4.
Information used for the meta-analyses of interventions to prevent or delay type 2 diabetes
| Trial | Intervention | Log hazard ratio (SE)* | Mean BMI (kg/m2) | Mean age (years) | Average follow-up (years) | Baseline risk† | Quality assessment‡ | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Concealed allocation | Randomisation | Blinding | Withdrawals and dropouts | Jadad score | ||||||||||||
| Lifestyle | ||||||||||||||||
| Da Qing,1997w22 | Diet | −0.45 (0.22) | 25.8 | 45.6 | 4.51* | 15.7 | No | 1 | 0 | 1 | 2 | |||||
| Jarrett, 1979w2 | Diet | −0.17 (0.39) | 26.2 | 56.7 | 4.39* | 2.6 | No | 1 | 0 | 1 | 2 | |||||
| Wein, 1999w35 | Diet | −0.46 (0.30) | 25.4 | 38.7 | 4.25 | 7.1 | No | 1 | 0 | 1 | 2 | |||||
| Da Qing, 1997w22 | Exercise | −0.64 (0.23) | 25.8 | 45.3 | 4.62* | 15.7 | No | 1 | 0 | 1 | 2 | |||||
| Tao, 2004w21 | Both | −1.20 (0.57) | 25.4 | 51.0 | 2.58 | 17.0 | No | 1 | 0 | 1 | 2 | |||||
| Da Qing, 1997w22 | Both | −0.49 (0.23) | 26.3 | 45.5 | 4.52* | 15.7 | No | 1 | 0 | 1 | 2 | |||||
| DPP, 2002w23 | Both | −0.87 (0.11) | 34.0 | 50.4 | 2.80 | 11.0 | No | 1 | 0 | 0 | 1 | |||||
| DPS, 2003w25 | Both | −0.92 (0.22) | 31.2 | 55.0 | 3.20 | 7.4 | No | 1 | 0 | 0 | 1 | |||||
| Fang, 2004w19 | Both | −0.29 (0.39) | 25.0 | 48.0 | 3.88* | 10.0 | No | 2 | 0 | 1 | 3 | |||||
| IDDP, 2006w39 | Both | −0.47 (0.20) | 25.8 | 45.9 | 2.50 | 18.3 | No | 1 | 0 | 1 | 2 | |||||
| Kosaka, 2005w27 | Both | −1.24 (0.60) | 23.8 | 51.5* | 3.64 | 2.6 | No | 1 | 0 | 1 | 2 | |||||
| Liao, 2002w29 | Both | −0.66 (1.22) | 26.1 | 54.0 | 1.83* | 3.1 | No | 1 | 0 | 1 | 2 | |||||
| Pharmacological/herbal | ||||||||||||||||
| Fang, 2004w19 | Acarbose | −1.31 (0.55) | 24.8 | 48.7 | 4.14* | 10.0 | No | 2 | 0 | 1 | 3 | |||||
| Pan, 2003w31 | Acarbose | −0.51 (0.48) | 25.7 | 54.5 | 0.37 | 30.0 | No | 1 | 2 | 0 | 3 | |||||
| STOP-NIDDM, 2002w33 | Acarbose | −0.29 (0.09) | 30.9 | 54.5 | 3.30 | 12.6 | Yes | 2 | 0 | 1 | 3 | |||||
| Fang, 2004w19 | Flumamine | −0.84 (0.49) | 25.0 | 48.7 | 4.06* | 10.0 | No | 2 | 0 | 1 | 3 | |||||
| Eriksson, 2006w38 | Glipizide | −1.74 (1.10) | 28.1 | 56.5. | 1.32 | 23.8 | No | 1 | 2 | 1 | 4 | |||||
| DPP, 2002w23 | Metformin | −0.37 (0.10) | 34.0 | 50.6 | 2.80 | 11.0 | No | 1 | 1 | 0 | 2 | |||||
| IDDP, 2006w39 | Metformin | −0.43 (0.20) | 25.8 | 45.9 | 2.50 | 18.3 | No | 1 | 0 | 1 | 2 | |||||
| Li, 1999w30 | Metformin | −0.72 (0.71) | 26.2 | 49.5 | 0.92 | 7.1 | No | 1 | 1 | 1 | 3 | |||||
| Jarrett, 1979w2 | Phenformin | 0.01 (0.39) | 26.2 | 56.7 | 4.36* | 2.6 | No | 1 | 1 | 1 | 3 | |||||
| Heymsfield, 2000w28 | Orlistat | −0.95 (0.35) | 35.8 | 44.1 | 1.59 | 4.8 | No | 1 | 1 | 0 | 2 | |||||
| XENDOS, 2004w37 | Orlistat | −0.73 (0.31) | 37.3 | 43.0 | 2.78 | 5.9 | Yes | 1 | 2 | 0 | 3 | |||||
| Fan, 2005w20 | Jiangtang bushen | −1.14 (1.15) | 25.5 | 56.0 | 0.90* | 13.3 | No | 2 | 0 | 1 | 3 | |||||
| Studies not included in meta-analyses | ||||||||||||||||
| EDIT, 2003w3 | Acarbose and/or metformin | NA | 28.6 | 52.1 | NA | NA | NA | NA | NA | NA | NA | |||||
| JDPP, 2005w18 | Diet and exercise | NA | NA | NA | NA | NA | No | 1 | 0 | 0 | 1 | |||||
| Keen, 1973w36 | Tolbutamide or diet | NA | 56.5 | NA | NA | NA | No | 1 | 1 | 0 | 2 | |||||
| Tripod, 2002w34 | Troglitazone | NA | 37.0 | 43.0 | NA | 4.73 | Yes | 1 | 2 | 0 | 3 | |||||
Both=diet and exercise; NA=not available.
*Estimated from, or transformation of, original data.
†Incidence of type 2 diabetes per 100 person years in control group.
‡Quality assessed by allocation of concealment and Jadad score (comprises randomisation and blinding, both marked out of 2), and description of withdrawals and dropouts (marked out of 1). Total Jadad score was therefore out of 5.